

Rheumatoid Arthritis

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

Trial Status
Completed

Trial Runs In
11 Countries

Trial Identifier
NCT02833350 2016-000335-40
GA29350

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and safety of GDC-0853 in participants with moderate to severe active RA and an inadequate response to previous methotrexate (MTX) therapy (Cohort 1) or MTX and tumor necrosis factor (TNF) therapy who may have also had exposure to no more than one non-TNF inhibitor biologic (Cohort 2).

Genentech, Inc.
Sponsor

Phase 2
Phase

NCT02833350 2016-000335-40 GA29350
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years & <= 75 Years

Healthy Volunteers
No
